Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
SLV-154 Treatment of Metastatic Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Cereius
Deal Size : Undisclosed
Deal Type : Acquisition
Solve Therapeutics, Inc. Acquires Cereius, Inc., a Duke University Spin-Out
Details : Through the acquisition, SolveTx bolsters the development of cancer therapeutics with Cereius radiolabeling technology platform and next-generation radiotherapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Cereius
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Nerviano Medical Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, SolveTx will use NMS's proprietary linker-payload technology to develop and commercialize novel antibody-drug conjugates (ADCs) for up to four cancer targets selected by SolveTx.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Nerviano Medical Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement